BNIP3 Cancer Research Results

BNIP3, BCL2/adenovirus E1B interacting protein 3: Click to Expand ⟱
Source:
Type:
BNIP3 (BCL2/adenovirus E1B interacting protein 3) is a mitochondrial pro‐apoptotic protein that also plays a key role in hypoxia‐induced autophagy and mitophagy. Its expression in tumors has attracted attention because it can influence cancer cell survival under stress, and its expression level has been linked to prognosis in several cancer types.

BNIP3 is frequently overexpressed in cancers characterized by significant hypoxia and has been linked to poorer outcomes in pancreatic, breast, lung, colorectal, and brain cancers. However, its exact role can vary; therefore, while BNIP3 is a promising prognostic biomarker in many contexts, its clinical utility may improve when evaluated alongside other hypoxia and autophagy markers.

BNIP3 which is a protein stimulated by ROS and promotes apoptosis.
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
2626- Ba,    Molecular targets and therapeutic potential of baicalein: a review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
3003- RosA,    Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, FOXM1↓, cycD1/CCND1↓, CDK4↓, MMP9↓, HDAC2↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   NRF2↓, 1,   ROS↓, 1,   ROS↑, 2,   SOD↓, 1,   Trx1↑, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↓, 1,   cMyc↓, 1,   GlucoseCon↓, 1,   lactateProd↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 1,   BAX↑, 2,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp1↓, 1,   Casp3↑, 2,   Casp9↑, 1,   proCasp9↓, 1,   Cyt‑c↑, 1,   DR5↑, 1,   hTERT/TERT↓, 1,   MAPK↑, 1,   MDM2↓, 2,  

Protein Folding & ER Stress ⓘ

HSP27↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3↑, 3,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 2,   CDK4↓, 2,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   p‑ERK↓, 1,   FOXM1↓, 1,   HDAC2↓, 1,   mTOR↓, 1,   NOTCH↓, 1,   PI3K↓, 2,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↑, 2,   FAK↓, 1,   GIT1↓, 1,   MARK4↓, 1,   MMP2↓, 2,   MMP9↓, 2,   N-cadherin↓, 1,   Snail↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature ⓘ

p‑EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 3,  

Immune & Inflammatory Signaling ⓘ

ASC↑, 1,   ICAM-1↓, 1,   IL1↓, 1,   IL6↓, 1,   IL6↑, 1,   NF-kB↓, 2,   p‑p65↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers ⓘ

p‑EGFR↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   IL6↑, 1,  

Functional Outcomes ⓘ

AntiCan↓, 1,   cardioP↑, 1,  
Total Targets: 84

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   Ferroptosis↓, 1,   GSR↑, 1,   GSTs↑, 1,   lipid-P↓, 2,   NRF2↑, 2,   ROS↓, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   p‑AMPK↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   HMGB1↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 4,   RenoP↑, 1,  
Total Targets: 38

Scientific Paper Hit Count for: BNIP3, BCL2/adenovirus E1B interacting protein 3
1 Baicalein
1 Luteolin
1 Rosmarinic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:1125  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page